{"log_id": 1386379055911408414, "direction": 0, "words_result_num": 23, "words_result": [{"probability": {"variance": 0.006273, "average": 0.973331, "min": 0.606903}, "location": {"width": 655, "top": 213, "height": 38, "left": 205}, "words": "按照ECOG体力状况和既往治疗进行分层的治疗的log-rank检验的单侧p值"}, {"probability": {"variance": 0.000204, "average": 0.991919, "min": 0.951739}, "location": {"width": 253, "top": 249, "height": 30, "left": 206}, "words": "截止日期:2011年11月1日"}, {"probability": {"variance": 0.00117, "average": 0.988838, "min": 0.861207}, "location": {"width": 254, "top": 276, "height": 31, "left": 206}, "words": "截止日期:2010年8月31日"}, {"probability": {"variance": 0.001642, "average": 0.984954, "min": 0.813922}, "location": {"width": 754, "top": 291, "height": 46, "left": 208}, "words": "ORR使用风险比。风险比>1表明阿昔替尼组中发生缓解的可能性更高:风险比<1表明"}, {"probability": {"variance": 3e-06, "average": 0.998929, "min": 0.993248}, "location": {"width": 320, "top": 330, "height": 34, "left": 206}, "words": "索拉非尼组中发生缓解的可能性更高"}, {"probability": {"variance": 0.00036, "average": 0.991906, "min": 0.932103}, "location": {"width": 458, "top": 357, "height": 34, "left": 206}, "words": "按照ECOG体力状况和既往治疗进行分层的治疗的C"}, {"probability": {"variance": 0.00023, "average": 0.98722, "min": 0.950606}, "location": {"width": 239, "top": 352, "height": 24, "left": 722}, "words": " Mantel- Haenszel检验的单侧"}, {"probability": {"variance": 6.4e-05, "average": 0.97628, "min": 0.968288}, "location": {"width": 43, "top": 393, "height": 24, "left": 201}, "words": "p值"}, {"probability": {"variance": 0.010878, "average": 0.963089, "min": 0.432009}, "location": {"width": 557, "top": 409, "height": 36, "left": 206}, "words": "按照ECOG体力状况进行分层的治疗的logrank检验的单侧p值"}, {"probability": {"variance": 0.00075, "average": 0.98841, "min": 0.903263}, "location": {"width": 436, "top": 440, "height": 33, "left": 206}, "words": "按照ECOG体力状况进行分层的治疗的 Cochran-M"}, {"probability": {"variance": 8e-06, "average": 0.996025, "min": 0.992105}, "location": {"width": 141, "top": 435, "height": 26, "left": 763}, "words": "检验的单侧p值"}, {"probability": {"variance": 0.001048, "average": 0.985393, "min": 0.856551}, "location": {"width": 636, "top": 542, "height": 41, "left": 182}, "words": "图1.独立评估的所有人群的无进展生存期的 Kaplan- Meier曲线"}, {"probability": {"variance": 2.9e-05, "average": 0.993933, "min": 0.982658}, "location": {"width": 124, "top": 630, "height": 21, "left": 767}, "words": " INLYTA(N=361"}, {"probability": {"variance": 1.3e-05, "average": 0.995032, "min": 0.991766}, "location": {"width": 144, "top": 653, "height": 20, "left": 763}, "words": " Median 6.8 month"}, {"probability": {"variance": 0.017779, "average": 0.743095, "min": 0.601283}, "location": {"width": 225, "top": 683, "height": 172, "left": 828}, "words": "08雅"}, {"probability": {"variance": 0.001195, "average": 0.9754, "min": 0.888403}, "location": {"width": 202, "top": 688, "height": 34, "left": 707}, "words": " o-- Sorafenib (N=362)"}, {"probability": {"variance": 0, "average": 0.985088, "min": 0.985088}, "location": {"width": 58, "top": 716, "height": 16, "left": 764}, "words": " Mediar"}, {"probability": {"variance": 0, "average": 0.76339, "min": 0.76339}, "location": {"width": 16, "top": 715, "height": 15, "left": 890}, "words": " nth"}, {"probability": {"variance": 0.009246, "average": 0.894274, "min": 0.79812}, "location": {"width": 96, "top": 759, "height": 18, "left": 769}, "words": " Hazard Ratio"}, {"probability": {"variance": 0.002197, "average": 0.895489, "min": 0.848613}, "location": {"width": 41, "top": 799, "height": 22, "left": 767}, "words": " P val"}, {"probability": {"variance": 0.008774, "average": 0.906329, "min": 0.812658}, "location": {"width": 36, "top": 1006, "height": 18, "left": 637}, "words": " iths)"}, {"probability": {"variance": 0.00548, "average": 0.962175, "min": 0.765013}, "location": {"width": 139, "top": 1581, "height": 23, "left": 550}, "words": "第18页,共27页"}, {"probability": {"variance": 1e-06, "average": 0.997947, "min": 0.997146}, "location": {"width": 18, "top": 1612, "height": 19, "left": 281}, "words": "20"}], "language": 3}